Centrifugal Compressor Performance Making Enlightened Analysis Decisions

Tutoria

Compression and Erdos-Ko-Rado graphs

For a graph G and integer r >= 1 we denote the collection of independent r-setsof G by I^(r)(G). If v is in V(G) then I^(r)_v(G) is the collection of all independent r-sets containing v. A graph G is said to be r-EKR, for r >= 1, iff no intersecting family A of I^(r)(G) is larger than max_{v in V(G)} |I^(r)_v(G)|. There are various graphs that are known to have this property; the empty graph of order n >= 2r (this is the celebrated Erdos-Ko-Rado theorem), any disjoint union of atleast r copies of K_t for t >= 2, and any cycle. In this paper we show how these results can be extended to other classes of graphs via a compression proof technique. In particular we extend a theorem of Berge, showing that any disjoint union of at least r complete graphs, each of order at least two, is r-EKR. We also show that paths are r-EKR for all r >= 1

Centrifugal Compressor Performance Making Enlightened Analysis Decisions

Tutoria

Efficacy of atomoxetine in adult attention-Deficit/Hyperactivity Disorder: a drug-placebo response curve analysis

BACKGROUND: The objective of this study was to evaluate the efficacy of atomoxetine, a new and highly selective inhibitor of the norepinephrine transporter, in reducing symptoms of attention-deficit/hyperactivity disorder (ADHD) among adults by using drug-placebo response curve methods. METHODS: We analyzed data from two double-blind, placebo-controlled, parallel design studies of adult patients (Study I, N = 280; Study II, N = 256) with DSM-IV-defined ADHD who were recruited by referral and advertising. Subjects were randomized to 10 weeks of treatment with atomoxetine or placebo, and were assessed with the Conners Adult ADHD Rating Scales and the Clinical Global Impression of ADHD Severity scale before and after treatment. RESULTS: Those treated with atomoxetine were more likely to show a reduction in ADHD symptoms than those receiving placebo. Across all measures, the likelihood that an atomoxetine-treated subject improved to a greater extent than a placebo-treated subject was approximately 0.60. Furthermore, atomoxetine prevented worsening of most symptom classes. CONCLUSION: From these findings, we conclude that atomoxetine is an effective treatment for ADHD among adults when evaluated using several criteria

Efficacy of Atomoxetine in Adult Attention-Deficit/Hyperactivity Disorder: A Drug-placebo Response Curve Analysis

Background: The objective of this study was to evaluate the efficacy of atomoxetine, a new and highly selective inhibitor of the norepinephrine transporter, in reducing symptoms of attention-deficit/hyperactivity disorder (ADHD) among adults by using drug-placebo response curve methods. Methods: We analyzed data from two double-blind, placebo-controlled, parallel design studies of adult patients (Study I, N = 280; Study II, N = 256) with DSM-IV-defined ADHD who were recruited by referral and advertising. Subjects were randomized to 10 weeks of treatment with atomoxetine or placebo, and were assessed with the Conners Adult ADHD Rating Scales and the Clinical Global Impression of ADHD Severity scale before and after treatment. Results: Those treated with atomoxetine were more likely to show a reduction in ADHD symptoms than those receiving placebo. Across all measures, the likelihood that an atomoxetine-treated subject improved to a greater extent than a placebo-treated subject was approximately 0.60. Furthermore, atomoxetine prevented worsening of most symptom classes. Conclusion: From these findings, we conclude that atomoxetine is an effective treatment for ADHD among adults when evaluated using several criteria

The relative noise levels of parallel axis gear sets with various contact ratios and gear tooth forms

The real noise reduction benefits which may be obtained through the use of one gear tooth form as compared to another is an important design parameter for any geared system, especially for helicopters in which both weight and reliability are very important factors. This paper describes the design and testing of nine sets of gears which are as identical as possible except for their basic tooth geometry. Noise measurements were made at various combinations of load and speed for each gear set so that direct comparisons could be made. The resultant data was analyzed so that valid conclusions could be drawn and interpreted for design use

Evaluation de la stratégie de prévention du sida en Suisse sur mandat de l'Office fédéral de la santé publique.: sixième rapport de synthèse 1996-1998

[Table des matières] I. Evaluation de la mise en oeuvre de la stratégie. 1. Campagne STOP-SIDA. 2. Réduction des risques liés au VIH/sida dans le domaine de la toxicomanie. 3. Prévention du VIH/sida en milieu carcéral. 4. "La santé des femmes - Prévention du VIH/sida" : programme d'action 1994-1998. 5. Le programme HSH ("Hommes ayant des rapports sexuels avec d'autres hommes"). 6. Le projet PAMiR de prévention du sida dans le domaine du voyage. 7. Travail avec des médiateurs dans la prévention du sida. - II. Evaluation des résultats de la stratégie de prévention. 1. Population générale. 2. Adolescents et jeunes adultes. 3. Les hommes ayant des relations sexuelles avec d'autres hommes. 4. Consommmateurs de drogues. 5. Epidémiologie du VIH/sida en Suisse. - III. Quelques aspects du contexte psycho-social.1. Discrimination, stigmatisation. 2. Les nouveaux traitements contre le sida : premiers effets pour la prévention dans la population. 3. La sexualité de personnes vivant avec le VIH/sida. 4. Coopération entre les partenaires politiques dans la prévention du sida. 5. la problématique du VIH/sida dans la presse suisse. 6. Prévention du VIH/sida : bilan d'une décennie et perspectives. - Annexes : 1. Evolution du nombre de contacts et de seringues distribuées dans les SBS en Suisse 1993-1997. 2. Perception de l'utilité d'un local d'injection. 3. Séjour en prison de la clientèle des structures à bas seuil en Suisse : 1993 à 1996. 4. Consommation et partage de matériel d'injection, clientèle des structures. 5. Principaux projets suisses avec "médiateurs". 6. Typologie des projets "Médiateurs". 7. Proportions (%) d'utilisateurs de préservatifs durant les 6 derniers mois ayant fait l'expérience de ruptures ou de glissements lors de l'utilisation. 8. Distribution (%) du nombre total de partenaires durant la vie. 9. Partage de seringues et test VIH - rapporté ou mesuré - dans diverses populations de consommateurs de drogues : 1989-1997

Influence of Gear Design Parameters on Gearbox Radiated Noise

Spur and helical gears were tested in the NASA gear-noise rig to compare the noise produced by different gear designs. Sound power measurements were performed under controlled conditions for a matrix of operating conditions. Sound power was computed from near-field acoustic intensity scans taken just above the top surface of the gearbox. Test gears included four spur and five helical gear designs. The gears were designed to be as nearly identical as possible except for deliberate differences in tooth geometry and contact ratio. Test results are presented as a function of the gear design and operating conditions in the form of sound power charts and as narrow-band spectra

Long-term neprilysin gene transfer is associated with reduced levels of intracellular Abeta and behavioral improvement in APP transgenic mice

<p>Abstract</p> <p>Background</p> <p>Proteolytic degradation has emerged as a key pathway involved in controlling levels of the Alzheimer's disease (AD)-associated amyloid-β (Aβ) peptide in the brain. The endopeptidase, neprilysin, has been implicated as a major Aβ degrading enzyme in mice and humans. Previous short and intermediate term studies have shown the potential therapeutic application of neprilysin by delivering this enzyme into the brain of APP transgenic mice using gene transfer with viral vectors. However the effects of long-term neprilysin gene transfer on other aspects of Aβ associated pathology have not been explored yet in APP transgenic mice.</p> <p>Results</p> <p>We show that the sustained expression of neprilysin for up to 6 months lowered not only the amyloid plaque load but also reduced the levels of intracellular Aβ immunoreactivity. This was associated with improved behavioral performance in the water maze and ameliorated the dendritic and synaptic pathology in the APP transgenic mice.</p> <p>Conclusion</p> <p>These data support the possibility that long-term neprilysin gene therapy improves behavioral and neurodegenerative pathology by reducing intracellular Aβ.</p

Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients With Advanced Cancer and Bone Metastases Treated With Bone Antiresorptive Agents

Purpose: Bone antiresorptive agents can significantly reduce bone turnover markers (BTMs) in patients with advanced cancer. We evaluated association of changes in BTMs with overall survival (OS), disease progression (DP), and disease progression in bone (DPB) in patients with advanced cancer and bone metastases following denosumab or zoledronic acid treatment. Experimental Design: This is an integrated analysis of patient-level data from three identically designed, blinded, phase III trials with patients randomized to subcutaneous denosumab or intravenous zoledronic acid. Levels of the BTMs urinary N-telopeptide (uNTx) and serum bone-specific alkaline phosphatase (sBSAP) measured at study entry and month 3 were analyzed. OS, DP, and DPB were compared in patients with BTMs {greater than or equal to} median vs < median based on month 3 assessments. Results: uNTx levels {greater than or equal to} the median of 10.0 nmol/mmol at month 3 were associated with significantly reduced OS compared with levels < median (HR for death 1.85, P<0.0001). sBSAP levels {greater than or equal to} median of 12.6 ng/mL were associated with significantly reduced OS compared with levels < median (HR 2.44, P<0.0001). uNTx and sBSAP levels {greater than or equal to} median at month 3 were associated with significantly greater risk of DP (HR 1.31, P<0.0001 and HR 1.71, P<0.0001, respectively) and DPB (HR 1.11, P=0.0407 and HR 1.27, P<0.0001, respectively). Conclusions: BTM levels {greater than or equal to} median after 3 months of bone antiresorptive treatment were associated with reduced OS and increased risk of DP and DPB. Assessment of uNTx and sBSAP levels after bone antiresorptive therapy may add to identification of patients at risk for worse clinical outcomes